HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16

Share this content:
Preparing a vaccination.
Preparing a vaccination.

Vaccination against human papilloma virus (HPV) alone is not effective in combating invasive HPV-driven cancer. Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies have shown promising results, but only produces tumor regression in a minority of patients with HPV-related cancer. In a recent study published in JAMA Oncology, researchers investigated if the efficacy of programmed cell death 1 immune checkpoint inhibition was increased by a tumor specific vaccine in patients with incurable HPV-16 cancer.

A total of 24 patients with incurable HPV-16 cancer were enrolled in a phase 2 clinical trial from December 23, 2015, to December 12, 2016, with a 12-month follow-up period through August 31, 2017. The HPV-16 vaccine, ISA101 was administered subcutaneously on days 1, 22, and 50, and the PD-1 inhibitor, nivolumab was administered intravenously every 2 weeks starting at day 8 for a total of 1 year.

The overall response rate to treatment was 33%, with a median duration of response of 10.3 months. At the time of publication, 5 of 8 patients remained responsive to treatment. The median progression-free survival was 2.7 months; and the median overall survival was 17.5 months. Two patients experienced adverse effects of grades 3-4 toxicity and were discontinued from the nivolumab therapy. 

According to the authors the results are, “promising compared with PD-1 inhibition alone in similar patients. A randomized clinical trial to confirm the contribution of HPV-16 vaccination to tumoricidal effects of PD-1 inhibition is warranted for further study.”


Massarelli E, William W, Johnson F, et al.Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer. A phase 2 clinical trial[published online September 27, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.4051

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs